pdk-1 Antibody
Description
PDK1 Antibody Overview
PDK1 antibodies target the serine/threonine kinase encoded by the PDPK1 gene, which regulates downstream effectors like AKT, PKC, and S6K . Key characteristics include:
-
Molecular Weight: Varies between 44–68 kDa depending on isoform and species .
-
Cellular Localization: Cytoplasmic and plasma membrane distribution, with nuclear translocation observed in cancer progression .
-
Biological Roles: Modulates glucose metabolism, hypoxia responses, apoptosis resistance, and oncogenic signaling .
Cancer Studies
-
Breast Cancer: PDK1 promotes metastasis by coordinating EGF-induced AKT/PKCζ translocation and actin polymerization . Knockdown reduces tumorigenesis in murine models .
-
Ovarian Cancer: High PDK1 expression correlates with advanced FIGO stage, metastasis, and poor prognosis. Silencing PDK1 induces apoptosis and S-phase arrest .
-
Therapeutic Targeting: PDK1 inhibitors show promise in blocking PI3K/AKT-driven tumors .
Metabolic Regulation
-
PDK1 phosphorylates pyruvate dehydrogenase to suppress mitochondrial glucose oxidation, favoring glycolysis (Warburg effect) in cancers .
-
In diabetes, PDK1 protects neurons from hyperglycemia-induced damage and regulates insulin signaling .
Immune Function
-
PDK1 is essential for B cell survival, germinal center formation, and antibody responses. Conditional knockout mice show defective marginal zone and B-1 cell populations .
Clinical Relevance
-
Prognostic Biomarker: PDK1 overexpression predicts poor survival in ovarian and breast cancers .
-
Therapeutic Resistance: PDK1 mediates chemoresistance in cancer cells via anti-apoptotic signaling .
-
Combination Biomarkers: PDK1 with CA125 improves ovarian cancer prognosis prediction (AUC = 0.73 vs. 0.60 for CA125 alone) .
Technical Considerations
-
Validation: Antibodies like MA5-15797 and 10026-1-AP are validated across multiple platforms, including WB and IHC .
-
Cross-Reactivity: Clone MAB864 detects PDK1 in human, mouse, and rat samples, while AF864 is human-specific .
-
Storage: Most antibodies require storage at -20°C with avoidance of freeze-thaw cycles .
Key Research Findings
-
Mechanistic Insight: PDK1 activation requires phosphoinositide binding to its pleckstrin homology domain, enabling AKT recruitment to membranes .
-
Developmental Role: PDK1-deficient mice exhibit embryonic lethality, underscoring its role in growth signaling .
-
Dual Isoforms: Human PDK1 has 49 kDa and 52 kDa isoforms, with the former predominant in mature cells .
Product Specs
**Constituents:** 50% Glycerol, 0.01M PBS, pH 7.4
Target Background
- At least three C. elegans MTMs play essential roles in coelomocyte endocytosis, a process that also requires VPS34 (PI3K). PMID: 12788949
Q&A
Basic Research Questions
How do I validate PDK-1 antibody specificity for Western blotting?
Validate using:
-
Molecular weight confirmation: Compare observed bands (46–55 kDa) with predicted sizes (49 kDa for full-length PDK1). Use lysates from PDK1-knockout cells as negative controls .
-
Isoform cross-reactivity tests: Assess reactivity against PDK1 isoforms (e.g., 49 kDa vs. 52 kDa) using overexpression systems .
-
Orthogonal validation: Cross-verify with siRNA knockdown followed by immunoblotting or functional assays (e.g., lactate production assays) .
What factors influence antibody performance in IHC for PDK1 localization studies?
-
Fixation method: Prolonged formalin fixation may mask epitopes; optimize antigen retrieval using citrate buffer (pH 6.0) .
-
Tissue-specific considerations: Metastatic ovarian cancer samples show higher PDK1 expression than primary tumors; include positive controls (e.g., metastatic lymph nodes) .
-
Antibody dilution: Titrate antibodies (e.g., 1:100–1:500) to balance signal-to-noise ratios .
How to select between monoclonal and polyclonal PDK1 antibodies?
Advanced Research Questions
How to resolve contradictory PDK1 expression data across cancer models?
-
Context-dependent analysis: PDK1 promotes metastasis in ovarian cancer but shows variable roles in melanoma . Use pathway-specific assays (e.g., α5β1 integrin/JNK/IL-8 signaling in metastasis) .
-
Model stratification: Compare in vitro (2D monolayers) vs. in vivo (metastatic xenografts) systems, as PDK1’s role in hypoxia differs .
-
Transcriptomic profiling: Pair antibody-based protein detection with RNA-seq to identify post-translational regulation .
What methods confirm PDK1’s co-regulation with metabolic pathways in live cells?
-
Multiplex assays: Combine PDK1 immunofluorescence with real-time metabolic probes (e.g., Seahorse XF Analyzer for glycolysis/OXPHOS) .
-
Pharmacological inhibition: Treat cells with PDK1 inhibitors (e.g., dichloroacetate) and monitor phosphorylation of pyruvate dehydrogenase (PDH E1α) .
-
Co-IP/MS: Identify PDK1 interactomes (e.g., α5β1 integrin, JNK) using validated antibodies in immunoprecipitation workflows .
How to design PDK1-focused studies in immune cell activation?
-
Conditional knockout models: Use Cre-lox systems in T cells to study PDK1’s role in CD69 upregulation and IL-2 production .
-
Functional readouts: Measure TCR-CD28-induced NF-κB activation via luciferase reporters in PDK1-depleted Jurkat cells .
-
Cross-species validation: Test antibody reactivity in murine T cells (e.g., clone MA5-15797 for non-human primates) .
